Studies

Interventional Recruiting Phase 2 Enrollment (Estimated) Enrollment 23 (Estimated)

View on ClinicalTrials.gov NCT04837885 Other Study ID: CHUBX 2017/47

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

See official title

Sponsor: See the organization Hôpital Saint-André

First Submitted: April 6, 2021

Last Update Posted: July 23, 2025

Brief Summary

The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options. As liver is the most frequent site of metastatic disease, our project proposes to compare administration of radiolabeled SSA by arterial intrahepatic infusion (experimental approach) vs intravenous administration (conventional). Evaluation will be made by (i) comparing 68Ga-DOTA-peptides uptake after intra-hepatic versus intravenous route (imaging), (ii) by evaluating the safety of an additional intra-hepatic administration of therapeutic radiolabeled SSA (therapy).

Conditions

  • Neuroendocrine Tumor
  • •
  • Liver Metastases
  • •
  • Neuroendocrine Gastroenteropancreatic Tumour

Intervention / Treatment

  • Procedure Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection
  • Procedure Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection
  • Drug LUTATHERA® by intra-arterial hepatic (IAH) injection
  • Procedure Scan

Contacts and Locations

Nimes Cedex 9

France, 30029

Centre Hospitalier Universitaire De Nimes

Bordeaux

France, 33000

Institut Bergonie

Toulouse

France, 31100

Oncopole Claudius Regaud

Montpellier Cedex 5

France, 34298

Institut Regional Du Cancer De Montpellier

Participation Criteria

Participant Groups/Arms

68Ga-DOTA-peptides PET/CT

EXPERIMENTAL

68Ga-DOTA-peptides injections for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT) One treatment dose of LUTATHERA® by intra-arterial hepatic injection (IAH) after conventional treatment by 4 intravenous administrations

Diseases

  • Digestive System Diseases

Collaborators and Investigators

Collaborators

  • Advanced Accelerator Applications

Keywords

  • Neuroendocrine tumour
  • •
  • Neuroendocrine gastroenteropancreatic (GEP) tumour
  • •
  • Liver Metastases
  • •
  • 68Ga- DOTA-peptides PET CT
  • •
  • 177Lutetium-Octreotate
  • •
  • Peptide Receptor Radionuclide Therapy

References

No references provided.

Outcome Measures